Parallel Advisors LLC bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,324 shares of the company’s stock, valued at approximately $2,689,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. L & S Advisors Inc bought a new position in shares of AstraZeneca during the fourth quarter worth $14,863,000. Burling Wealth Partners LLC bought a new position in shares of AstraZeneca during the fourth quarter worth $4,532,000. Hendley & Co. Inc. bought a new position in shares of AstraZeneca during the fourth quarter worth $11,373,000. Saranac Partners Ltd bought a new position in shares of AstraZeneca during the third quarter worth $876,000. Finally, Root Financial Partners LLC bought a new position in shares of AstraZeneca during the fourth quarter worth $622,000. Institutional investors own 40.87% of the company’s stock.
AstraZeneca Stock Performance
Shares of OTCMKTS:AZNCF opened at $187.10 on Friday. The firm has a fifty day moving average price of $187.10 and a 200 day moving average price of $185.66. AstraZeneca PLC has a fifty-two week low of $122.26 and a fifty-two week high of $195.00.
AstraZeneca Company Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
